Brokers Issue Forecasts for Neurogene FY2027 Earnings

Neurogene Inc. (NASDAQ:NGNE) – Research analysts at William Blair issued their FY2027 earnings per share estimates for Neurogene in a research report issued on Wednesday, November 12th. William Blair analyst S. Corwin anticipates that the company will post earnings of ($5.55) per share for the year. The consensus estimate for Neurogene’s current full-year earnings is ($4.27) per share. William Blair also issued estimates for Neurogene’s FY2028 earnings at ($5.03) EPS.

Neurogene (NASDAQ:NGNE) last posted its quarterly earnings data on Thursday, November 13th. The company reported ($0.99) EPS for the quarter, topping analysts’ consensus estimates of ($1.26) by $0.27.

Other analysts have also issued research reports about the stock. HC Wainwright lifted their price objective on shares of Neurogene from $65.00 to $70.00 and gave the company a “buy” rating in a research note on Thursday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Neurogene in a research note on Wednesday, October 8th. Finally, Wall Street Zen raised shares of Neurogene from a “sell” rating to a “hold” rating in a research report on Saturday. Four investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Neurogene currently has a consensus rating of “Hold” and a consensus price target of $42.50.

Neurogene Stock Performance

Shares of NGNE stock opened at $22.77 on Monday. The company has a market cap of $324.97 million, a P/E ratio of -5.28 and a beta of 1.64. The stock has a 50 day simple moving average of $25.27 and a two-hundred day simple moving average of $21.46. Neurogene has a fifty-two week low of $6.88 and a fifty-two week high of $39.20.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Baker BROS. Advisors LP increased its stake in Neurogene by 120.4% in the 1st quarter. Baker BROS. Advisors LP now owns 1,486,200 shares of the company’s stock valued at $17,403,000 after buying an additional 811,750 shares during the last quarter. Balyasny Asset Management L.P. purchased a new stake in shares of Neurogene during the third quarter valued at approximately $12,114,000. Blair William & Co. IL lifted its holdings in Neurogene by 141.3% during the first quarter. Blair William & Co. IL now owns 151,180 shares of the company’s stock worth $1,770,000 after acquiring an additional 88,540 shares during the period. Jennison Associates LLC boosted its position in Neurogene by 55.0% in the second quarter. Jennison Associates LLC now owns 167,563 shares of the company’s stock worth $2,505,000 after purchasing an additional 59,479 shares during the last quarter. Finally, Bank of America Corp DE boosted its position in Neurogene by 81.6% in the second quarter. Bank of America Corp DE now owns 95,401 shares of the company’s stock worth $1,426,000 after purchasing an additional 42,880 shares during the last quarter. 52.37% of the stock is currently owned by hedge funds and other institutional investors.

Neurogene Company Profile

Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.